EP3481399A4 - Verfahren zur behandlung von herzinsuffizienz - Google Patents

Verfahren zur behandlung von herzinsuffizienz Download PDF

Info

Publication number
EP3481399A4
EP3481399A4 EP17825050.2A EP17825050A EP3481399A4 EP 3481399 A4 EP3481399 A4 EP 3481399A4 EP 17825050 A EP17825050 A EP 17825050A EP 3481399 A4 EP3481399 A4 EP 3481399A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
heart failure
heart
failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17825050.2A
Other languages
English (en)
French (fr)
Other versions
EP3481399A1 (de
Inventor
Michael E. Mendelsohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals LLC
Original Assignee
Cardurion Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals LLC filed Critical Cardurion Pharmaceuticals LLC
Publication of EP3481399A1 publication Critical patent/EP3481399A1/de
Publication of EP3481399A4 publication Critical patent/EP3481399A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17825050.2A 2016-07-07 2017-07-07 Verfahren zur behandlung von herzinsuffizienz Withdrawn EP3481399A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359695P 2016-07-07 2016-07-07
PCT/US2017/041249 WO2018009899A1 (en) 2016-07-07 2017-07-07 Methods for treatment of heart failure

Publications (2)

Publication Number Publication Date
EP3481399A1 EP3481399A1 (de) 2019-05-15
EP3481399A4 true EP3481399A4 (de) 2020-04-01

Family

ID=60912319

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17825050.2A Withdrawn EP3481399A4 (de) 2016-07-07 2017-07-07 Verfahren zur behandlung von herzinsuffizienz

Country Status (7)

Country Link
US (2) US10870656B2 (de)
EP (1) EP3481399A4 (de)
JP (1) JP2019521192A (de)
KR (1) KR20190049691A (de)
AU (1) AU2017292918B2 (de)
CA (1) CA3030021A1 (de)
WO (1) WO2018009899A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781155A4 (de) 2018-04-17 2021-10-06 Cardurion Pharmaceuticals, LLC Megluminsalze von thienopyrimidinen
TWI816026B (zh) * 2019-03-08 2023-09-21 大陸商藥捷安康(南京)科技股份有限公司 磷酸二酯酶抑制劑的用途和藥盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203703A1 (en) * 2005-06-14 2009-08-13 Kotaro Gotanda Thienopyrimidine Derivatives
US8299083B2 (en) * 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2015052065A1 (de) * 2013-10-07 2015-04-16 Bayer Pharma Aktiengesellschaft Cyclische thienouracil-carboxamide und ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
EP2402347A1 (de) * 2006-04-26 2012-01-04 F. Hoffmann-La Roche AG Pharmazeutische Verbindungen
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CN103038238B (zh) * 2010-05-31 2016-05-04 Aska制药株式会社 噻吩并嘧啶衍生物的结晶

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299083B2 (en) * 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US20090203703A1 (en) * 2005-06-14 2009-08-13 Kotaro Gotanda Thienopyrimidine Derivatives
WO2015052065A1 (de) * 2013-10-07 2015-04-16 Bayer Pharma Aktiengesellschaft Cyclische thienouracil-carboxamide und ihre verwendung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONG I. LEE ET AL: "Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease", NATURE, vol. 519, no. 7544, 1 March 2015 (2015-03-01), London, pages 472 - 476, XP055671367, ISSN: 0028-0836, DOI: 10.1038/nature14332 *
NOMOTO YUJI ET AL: "Studies on cardiotonic agents. VI. Synthesis of novel 4,5-dihydro-3(2H)-pyridazinone derivatives carrying some benzoheterocycles at the 6-position", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 39, no. 2, 1 January 1991 (1991-01-01), pages 352 - 357, XP009519042, ISSN: 0009-2363, DOI: 10.1248/CPB.39.352 *
See also references of WO2018009899A1 *

Also Published As

Publication number Publication date
EP3481399A1 (de) 2019-05-15
JP2019521192A (ja) 2019-07-25
US10870656B2 (en) 2020-12-22
WO2018009899A1 (en) 2018-01-11
US20210261567A1 (en) 2021-08-26
AU2017292918B2 (en) 2021-11-11
AU2017292918A1 (en) 2019-02-07
US20190211028A1 (en) 2019-07-11
KR20190049691A (ko) 2019-05-09
CA3030021A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
EP3426250A4 (de) Behandlungsverfahren
EP3212233A4 (de) Kombinationstherapie zur behandlung einer krankheit
EP3171786A4 (de) Vorrichtungen und verfahren zur behandlung von herzinsuffizienz
EP3261713A4 (de) Blutpumpe zur behandlung von bradykardie
EP3240612A4 (de) Verfahren zur behandlung von netzhauterkrankungen
EP3374502A4 (de) Verfahren zur behandlung von hornhautdystrophien
EP3183240A4 (de) Behandlung von gelenkerkrankungen
EP3169259A4 (de) Kardialcryolipolyse zur behandlung von herzrhythmusstörungen
EP3684342A4 (de) Behandlungsverfahren
EP3345002A4 (de) Auswahl von patienten für kombinationstherapie
EP3340974A4 (de) Verfahren zur behandlung von erkrankungen
EP3253401A4 (de) Verfahren zur behandlung von krankheiten
EP3256137A4 (de) Verfahren zur behandlung von herzversagen
EP3236963A4 (de) Verfahren zur behandlung
EP3490547A4 (de) Verfahren zur behandlung
EP3259346A4 (de) P63-inaktivierung zur behandlung von herzinsuffizienz
EP3481399A4 (de) Verfahren zur behandlung von herzinsuffizienz
EP3601565A4 (de) Mir-92-inhibitoren zur behandlung von herzinsuffizienz
EP3242662A4 (de) Behandlung von filarienerkrankungen
EP3271017A4 (de) Behandlung von hauterkrankungen
IL275273A (en) An improved compound for the treatment of heart failure
EP3612178A4 (de) Vasodilatatoren zur behandlung von herzinsuffizienz
EP3727376A4 (de) Verfahren zur behandlung von hypertriglyceridämie
EP3503965B8 (de) Behandlung von herzfunktionsstörungen
EP3440462A4 (de) Verfahren zur behandlung von herzhypertrophie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101AFI20200227BHEP

Ipc: C07D 495/04 20060101ALI20200227BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220311

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220922